| __timestamp | Incyte Corporation | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 165772000 | 1244910 |
| Thursday, January 1, 2015 | 196614000 | 5029636 |
| Friday, January 1, 2016 | 303251000 | 4846776 |
| Sunday, January 1, 2017 | 366406000 | 5329003 |
| Monday, January 1, 2018 | 434407000 | 7121000 |
| Tuesday, January 1, 2019 | 468711000 | 9128000 |
| Wednesday, January 1, 2020 | 516922000 | 10731000 |
| Friday, January 1, 2021 | 739560000 | 10701000 |
| Saturday, January 1, 2022 | 1002140000 | 16121000 |
| Sunday, January 1, 2023 | 1161300000 | 37021000 |
| Monday, January 1, 2024 | 1242157000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, understanding financial trends is crucial. Over the past decade, Incyte Corporation and Viking Therapeutics, Inc. have shown distinct patterns in their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Incyte's SG&A expenses surged by over 600%, reflecting its aggressive growth strategy. By 2023, Incyte's spending reached a peak, indicating a robust investment in its operational infrastructure.
Conversely, Viking Therapeutics exhibited a more conservative approach, with a 2900% increase in SG&A expenses over the same period. This steady rise suggests a strategic focus on sustainable growth.
These spending patterns highlight the contrasting strategies of two biotech players, offering insights into their operational priorities and market positioning.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viking Therapeutics, Inc.
AstraZeneca PLC vs Viking Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Amgen Inc. vs Viking Therapeutics, Inc.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Incyte Corporation
BeiGene, Ltd. or Incyte Corporation: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Genmab A/S or Viking Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Viking Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Incyte Corporation and Ascendis Pharma A/S
SG&A Efficiency Analysis: Comparing Incyte Corporation and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Incyte Corporation and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Catalent, Inc. vs Viking Therapeutics, Inc. Trends and Insights
Viking Therapeutics, Inc. and Perrigo Company plc: SG&A Spending Patterns Compared